South Korean biotech convertible bonds become repayment burden as stocks plunge 26.9%
AI Summary- South Korean biotech and pharmaceutical companies face rising convertible-bond repayments after share-price declines.
- 26.9%: The KRX Health Care Index decline from last year's final trading session.
- Investors exercised at least 48 put options through Sept. 28, according to the reported data.